Superluminal Medicines raised a $60 million oversubscribed Series B to advance its AI-powered GPCR platform and to initiate its first clinical trial by year-end. The round was led by BVF Partners, with participation from Deep Track Capital and Perceptive Advisors and continued support from investors including RA Capital Management, Insight Partners, NVIDIA, and Eli Lilly. The company’s lead program is a selective, biased melanocortin-4 receptor (MC4R) agonist aimed at rare genetic obesity and hypothalamic obesity, conditions with limited effective options. Superluminal’s strategy is designed to activate specific MC4R signaling pathways while minimizing side effects. From an industry standpoint, the financing highlights continued appetite for mechanism-led GPCR assets that target defined patient subgroups. It also signals that clinical validation for biased agonism may be a key funding theme alongside AI-discovery approaches. Next milestones include the Phase I start and dose exploration across hypothalamic and genetic obesity indications.